<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03487133</url>
  </required_header>
  <id_info>
    <org_study_id>2017-02-104</org_study_id>
    <nct_id>NCT03487133</nct_id>
  </id_info>
  <brief_title>Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma</brief_title>
  <official_title>A Prospective, Multi-center, Open-label, Single-arm, Phase II Study of Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the efficacy and safety of bortezomib / dexamethasone combination therapy in patients with&#xD;
      relapsed or refractory T-cell lymphoma who have failed one or more treatments.&#xD;
&#xD;
        -  primary purpose&#xD;
&#xD;
           1. Overall response rate&#xD;
&#xD;
        -  secondary purpose&#xD;
&#xD;
             1. Progression-free survival and overall survival&#xD;
&#xD;
             2. Disease stabilization ratio&#xD;
&#xD;
             3. Duration of reaction&#xD;
&#xD;
             4. Safety Profile&#xD;
&#xD;
             5. Experiments on response prediction / immunological markers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a Phase II study in patients with previous T-cell lymphoma, bortezomib was administered at&#xD;
      a dose of 1.6 mg / m 2 on Day 1 and Day 8, and combined with CHOP (cyclophosphamide,&#xD;
      doxorubicin, vincristine and prednisolone) chemotherapy . The 1.6 mg / m2 dose of bortezomib&#xD;
      was obtained through phase 1 studies, and the Phase II study included five patients with skin&#xD;
      T-cell lymphoma, with an overall response rate of 87%. In addition, there was no significant&#xD;
      increase in toxicity when bortezomib was administered at 1.6 mg / m2 every week. The fact&#xD;
      that there was no increase in toxicity in combination with a drug commonly used to induce&#xD;
      peripheral neuropathy, such as vincristine, / m2 suggests the safety of the dosage at 1 week&#xD;
      intervals.Therefore, in order to improve the convenience of administration with once-weekly&#xD;
      dosing, this study combined 1.6 mg / m2 every week for 1 week, 2 weeks, and 3 weeks in a&#xD;
      4-week cycle, The dose was determined by a single dose.In addition, it is known that the main&#xD;
      dose-limiting toxicity of subcutaneous injection is significantly reduced in peripheral&#xD;
      neuropathy, so the route of administration was determined to be via subcutaneous&#xD;
      administration (18).Considering that one of the major difficulties in remediation of skin&#xD;
      T-cell lymphoma is the short duration of the response after termination of treatment, the&#xD;
      subjects who were considered to have a response to the test drug, that is, those who acquired&#xD;
      a stable lesion response after 8 cycles of induction therapy The test was designed so that&#xD;
      maintenance therapy can be performed up to one year.Even with one year of maintenance&#xD;
      therapy, there is no safety concern since the cumulative dose of the test drug is not higher&#xD;
      than the cumulative dose currently used as the primary treatment for multiple myeloma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 19, 2017</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate of tumor</measure>
    <time_frame>Through study completion, an average of 3 years</time_frame>
    <description>Overall response rate (complete remission, partial remission) according to the ISCL-USCLC-EORTC recommendation evaluated by institutional investigators</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progressive-free survival</measure>
    <time_frame>From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 72 months</time_frame>
    <description>the time interval between the first clinical trial dosing date and the first occurring date of tumor progression or death (due to all causes) Duration of response: The time from the first documentation of the objective tumor response to the time of disease progression or death (due to all causes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease stabilization rate</measure>
    <time_frame>An average of 6 years</time_frame>
    <description>Percentage of subjects who achieved complete remission, partial remission, or stable lesions as a result of tumor response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 72 months</time_frame>
    <description>The time from the first documentation of the objective tumor response to the time of disease progression or death (due to all causes)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Relapsed and/or Refractory Cutaneous T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>bortezomib/dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who have been diagnosed with stable lesions more than 4 cycles of induction therapy (Induction Therapy Part I) will receive additional induction therapy 4 cycles (Induction Therapy Part II) Patients who have been diagnosed with a stable disease response after a total of eight cycles of induction therapy receive up to one year of maintenance therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib/dexamethasone</intervention_name>
    <description>Induction therapy -&gt;1cycle=28 days 1,2,3week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 4week : none maintenance therapy -&gt;1cycle=28 days&#xD;
1week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 2,3,4week : none</description>
    <arm_group_label>bortezomib/dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically diagnosed subcutaneous skin T-cell lymphoma based on the WHO(World&#xD;
             Health Organization)-EORTC classification (mycosis fungoides, Sezary syndrome,primary&#xD;
             cutaneous anaplastic large cell lymphoma,lymphomatoid papulosis,primary cutaneous&#xD;
             peripheral T-cell lymphoma, unspecified)&#xD;
&#xD;
          -  Male and female patients aged 19-80&#xD;
&#xD;
          -  ECOG(Eastern Cooperative Oncology Group performance) 0~2&#xD;
&#xD;
          -  Presence of measurable lesion according to ISCL(International Society for Cutaneous&#xD;
             Lymphomas)-USCLC(United States Cutaneous Lymphoma Consortium)-EORTC(European&#xD;
             Organization of Research and Treatment of Cancer) recommendation&#xD;
&#xD;
          -  If one or more of the previous treatments fails or has recurred / progressed&#xD;
&#xD;
          -  Proper function status of bone marrow, kidney, liver&#xD;
&#xD;
          -  All toxic effects due to previous treatment have been resolved to CTCAE 4.03 version 1&#xD;
             or lower&#xD;
&#xD;
          -  For pregnant women, the result of pregnancy test is negative. (The pregnant female&#xD;
             patient should have effective contraception during the treatment period and for one&#xD;
             month thereafter) (ie, hormonal contraceptive device, intrauterine device, diaphragm&#xD;
             with spermicide, condom with spermicide, or abstinence) Men should use effective&#xD;
             contraception during the treatment period and for three months thereafter.)&#xD;
&#xD;
          -  Patients who are expected to follow and comply with the clinical trial protocol at the&#xD;
             discretion of the tester&#xD;
&#xD;
          -  Patients who voluntarily agreed to participate in this trial and signed a consent form&#xD;
&#xD;
          -  Patients who agreed to donate a sample of peripheral lesions (10 unstained slides) and&#xD;
             3 ml of peripheral blood after baseline and cycle 8&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing chemotherapy at the time of clinical trials&#xD;
&#xD;
          -  Patients who are undergoing radiotherapy at the time of their participation in the&#xD;
             trial or who received radiotherapy within the first 6 months of the trial. However,&#xD;
             patients who have additional lesions elsewhere in the main lesion may be eligible for&#xD;
             clinical trials if they have completed local radiotherapy as a palliative treatment&#xD;
             prior to the administration of the drug, and recovered from the resulting toxicity.&#xD;
&#xD;
          -  Patients with symptomatic or uncontrolled angina and congestive heart failure,&#xD;
             arrhythmia requiring drug therapy, significant risk of clinically significant&#xD;
             myocardial infarction within 6 months prior to participation in this trial&#xD;
&#xD;
          -  Patients with stable left ventricular ejection fraction less than the normal lower&#xD;
             limit of each organ.&#xD;
&#xD;
          -  Adverse Reactions Common Terminology Criteria 4.03 In case of infection in excess of&#xD;
             grade 2 according to the standards. Hepatitis B is allowed if there is no active&#xD;
             replication (HBV DNA&gt; 20,000 iU / mL associated with ALT(alanine aminotransferase)&#xD;
             exceeding twice the normal upper limit).&#xD;
&#xD;
          -  If there is active infection, including severe concomitant disease and / or active&#xD;
             hepatitis C and human immunodeficiency virus infection&#xD;
&#xD;
          -  Patients who received chemotherapy, surgical treatment (permissive for mild surgical&#xD;
             treatment) within 4 weeks of the administration of this drug&#xD;
&#xD;
          -  History of allogeneic transplantation (including hematopoietic stem cell&#xD;
             transplantation)&#xD;
&#xD;
          -  Patients with a malignant tumor other than the target disease. However, the following&#xD;
             cases are allowed.If you have not received treatment for the tumor for at least 5&#xD;
             years or have no disease,Complete resection of basal cell carcinoma / squamous cell&#xD;
             carcinoma or at least 1 year after successful treatment of cervical intraepithelial&#xD;
             cancer&#xD;
&#xD;
          -  Adverse reactions within 30 days prior to the start of screening Common Grade Criteria&#xD;
             4.03 Severe gastrointestinal bleeding in excess of grade 2&#xD;
&#xD;
          -  The occurrence of thrombosis or embolism within 6 months before screening&#xD;
&#xD;
          -  Patients with central nervous system involvement.&#xD;
&#xD;
          -  Pregnant, lactating, or reproductive women who are not willing to use appropriate&#xD;
             contraception during the trial&#xD;
&#xD;
          -  Unstable conditions that may impair patient safety and compliance with the test&#xD;
&#xD;
          -  Patients with seizure disorders requiring medication&#xD;
&#xD;
          -  If you have substance abuse, medical, mental or social illnesses that may interfere&#xD;
             with the patient's participation in the clinical trial or the evaluation of clinical&#xD;
             trial results&#xD;
&#xD;
          -  Patients with a history of hypersensitivity to Drug or Drug component (bortezomib,&#xD;
             boron, mannitol, dexamethasone)&#xD;
&#xD;
          -  Patients with Acute Diffuse Invasive Pulmonary Disease and Cardiovascular Disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seok Jin Kim</last_name>
    <role>Study Chair</role>
    <affiliation>81, Irwon-Ro, Gangnam-Gu, Seoul, Korea 135-710</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung medical center</name>
      <address>
        <city>Seoul</city>
        <state>Gang Nam</state>
        <zip>676</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>(1) Bradford PT, et al. Blood 2009; 113: 5064 (2) Criscione VD, et al. Arch Dermatol 2007; 143: 854 (3) Willemze R. et al. Blood 2005; 105: 3768 (4) Li JY, et al. Cancer Manag Res 2012; 4: 75 (5) Wilcox RA. Am J Hematol 2016; 91: 152 (6) Querfeld C, et al. Blood 2014; 123: 1159 (7) Kim YH, et al. J Am Acad Dermatol 2010; 63: 975 (8) Yamamoto K, et al. J Clin Oncol 2010; 28: 1591 (9) Bose P, et al. Exp Opin Pharmacother 2014; 15: 2443 (10) Manf√© V, et al. PLoS One 2013; 8: e59390 (11) Chang TP, et al. Am J Cancer Res 2013; 3: 433 (12) Chang TP, et al. J Immunol 2015; 194: 1942 (13) Ungewickell A, et al. Nat Genet 2015; 47: 1056 (14) Jagannath S, et al. Br J Haematol 2005; 129: 776 (15) Jagannath S, et al. Br J Haematol 2009; 146: 619 (16) Zinzani PL, et al. J Clin Oncol 2007; 25: 4293 (17) Kim SJ, et al. Eur J Cancer 2012; 48: 3223 (18) Moreau P, et al. Lancet Oncol 2011; 12: 431</citation>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>April 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2018</study_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Kim, Seok Jin</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

